Why the study?
Does N-acetylprocainamide reduce the incidence of systemic lupus erythematosus compared to procainamide in patients treated for cardiac arrhythmias?
Does N-acetylprocainamide reduce the incidence of systemic lupus erythematosus compared to procainamide in patients treated for cardiac arrhythmias?
N-acetylprocainamide is a safer alternative to procainamide for cardiac arrhythmias, as it retains antiarrhythmic efficacy without the high risk of inducing systemic lupus erythematosus.
Answers are grounded in this paper and cite their sources.
Supports NAPA preference to minimize SLE risk versus procainamide; hypothesis-generating without randomized confirmation in arrhythmia patients.
Long-term therapy with procainamide (PA) leads to the systemic lupus erythematosus syndrome (SLE) in about 30% of patients and 80% develop antinuclear antibodies. Acetylation of procainamide results in the formation of N-acetylprocainamide (NAPA) the propensity of which to induce SLE and to increase antinuclear antibodies is negligible while its antiarrhythmic properties remain. Slow acetylators of PA have a greater tendency to induce SLE consistent with the observation that it is the level of PA that is responsible for the observed immunologically-mediated side effects of the compound. This is also suggested by the remission of PA-induced SLE when PA is replaced with NAPA for the control of cardiac arrhythmias. Thus, NAPA, compared to the parent compound, has little tendency to induce SLE.
No takes yet. Share an insight, caveat, or question.
Reidenberg et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: